<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00161590</url>
  </required_header>
  <id_info>
    <org_study_id>0204-157</org_study_id>
    <nct_id>NCT00161590</nct_id>
  </id_info>
  <brief_title>Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma</brief_title>
  <official_title>Phase I Study of CHOP Plus Campath (C-CHOP) for the Treatment of T-Cell, Null-Cell, and NK-Cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        -  To determine the toxicity profile and tolerability of alemtuzumab (Campath) when&#xD;
           administered in combination with cyclophosphamide, doxorubicin, vincristine, and&#xD;
           prednisone (CHOP) chemotherapy (C-CHOP) in patients with T-cell, null-cell and NK-cell&#xD;
           lymphomas.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To evaluate response rate, overall survival, and disease-free survival in patients with&#xD;
           T-cell, null-cell, and NK-cell lymphomas treated with Campath + CHOP chemotherapy.&#xD;
&#xD;
        -  To assess the incidence of cytomegalovirus (CMV) reactivation in patients with these&#xD;
           lymphomas treated with the Campath + CHOP combination.&#xD;
&#xD;
        -  To determine features which might be predictive of resistance to treatment or predictive&#xD;
           of relapse, including the absence of glycosylphosphatidylinositol (GPI)-linked proteins.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>T-Cell Lymphoma</condition>
  <condition>Lymphoma, Non-Hodgkin's</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP and alemtuzumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a diagnosis of non-B-cell, non-Hodgkin's lymphoma (including&#xD;
             T-cell, null-cell, or NK-cell lymphoma, but excluding lymphoblastic lymphoma)&#xD;
&#xD;
          -  Stage II, III, or IV disease requiring chemotherapy&#xD;
&#xD;
          -  At least one site of measurable disease, 1.5 cm in diameter or greater&#xD;
&#xD;
          -  Age &gt; or = 18 years&#xD;
&#xD;
          -  Absolute granulocyte count of at least 1500 cells/mm3, unless neutropenia is due to&#xD;
             marrow infiltration by the tumor&#xD;
&#xD;
          -  Platelet count of at least 100,000 cells/mm3 unless thrombocytopenia is due to marrow&#xD;
             infiltration by tumor&#xD;
&#xD;
          -  Creatinine less than 2 x upper limits of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin less than 2 x ULN (dose reduced vincristine and adriamycin required&#xD;
             for bilirubin &gt; 1.2 mg/dL)&#xD;
&#xD;
          -  Echocardiogram (Echo) or multiple gate acquisition scan (MUGA) documenting a normal&#xD;
             ejection fraction prior to chemotherapy&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known central nervous system (CNS) involvement&#xD;
&#xD;
          -  Known HIV disease&#xD;
&#xD;
          -  Patients who are pregnant or nursing&#xD;
&#xD;
          -  Any factor which might limit the patient's ability to provide informed consent&#xD;
&#xD;
          -  Life expectancy &lt; 3 months&#xD;
&#xD;
          -  Patients who are unwilling to agree to use an effective means of birth control while&#xD;
             on treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Richard Furman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>October 21, 2008</last_update_submitted>
  <last_update_submitted_qc>October 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2008</last_update_posted>
  <keyword>NK cell lymphoma</keyword>
  <keyword>Null cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

